Low-density lipoprotein cholesterol goal attainment in patients with clinical evidence of familial hypercholesterolemia and elevated Lp(a)

被引:4
作者
Schwarz, Andrea [1 ,2 ,3 ,4 ,5 ]
Demuth, Ilja [1 ,2 ,3 ,4 ,6 ]
Landmesser, Ulf [7 ,8 ,9 ]
Haghikia, Arash [7 ,8 ,9 ]
Konig, Maximilian [1 ,2 ,3 ,4 ]
Steinhagen-Thiessen, Elisabeth [1 ,2 ,3 ,4 ,10 ]
机构
[1] Charite Univ Med Berlin, Dept Endocrinol & Metab Dis, Including Div Lipid Metab, Augustenburger Pl 1, D-13353 Berlin, Germany
[2] Charite Univ Med Berlin, Augustenburger Pl 1, D-13353 Berlin, Germany
[3] Free Univ Berlin, Augustenburger Pl 1, D-13353 Berlin, Germany
[4] Humboldt Univ, Biol Aging Working Grp, Augustenburger Pl 1, D-13353 Berlin, Germany
[5] Charite Univ Med Berlin, Div Cardiol, Dept Pediat, Berlin, Germany
[6] BCRT Berlin Inst Hlth Ctr Regenerat Therapies, Berlin, Germany
[7] Charith Univ Med Berlin, Berlin Inst Hlth, Berlin, Germany
[8] Charite Univ Med Berlin, Dept Cardiol, Campus Benjamin Franklin, Berlin, Germany
[9] German Ctr Cardiovasc Res DZHK, Partner Site Berlin, Berlin, Germany
[10] Univ Rostock, Inst Clin Chem & Lab Med, Rostock, Germany
关键词
LDL-cholesterol; Treatment goal achievement; Familial hypercholesterolemia; Lipoprotein (a); Coronary artery disease; Lipid-lowering treatment; Family history; LIPID-MODIFYING THERAPY; CARDIOVASCULAR RISK; HEART-DISEASE; ASSOCIATION; EZETIMIBE; HISTORY; ATORVASTATIN; SIMVASTATIN; GUIDELINE; DIAGNOSIS;
D O I
10.1186/s12944-022-01708-9
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Background Although potent lipid-lowering therapies are available, patients commonly fall short of recommended low-density lipoprotein cholesterol (LDL-C) levels. The aim of this study was to examine the relationship between familial hypercholesterolemia (FH) and elevated lipoprotein(a) [Lp(a)] and LDL-C goal attainment, as well as the prevalence and severity of coronary artery disease (CAD). Moreover, we characterized patients failing to meet recommended LDL-C goals. Methods We performed a cross-sectional analysis in a cohort of patients undergoing cardiac catheterization. Clinical FH was determined by the Dutch Clinical Lipid Network Score, and Lp(a) >= 50 mg/dL (approximate to 107 nmol/L) was considered elevated. Results A total of 838 participants were included. Overall, the prevalence of CAD was 72%, and 62% received lipid-lowering treatment. The prevalence of clinical FH (probable and definite FH) was 4%, and 19% had elevated Lp(a) levels. With 35%, LDL-C goal attainment was generally poor. Among the participants with clinical FH, none reached their LDL-C target. Among patients with elevated Lp(a), LDL-C target achievement was only 28%. The prevalence and severity of CAD were higher in participants with clinical FH (86% prevalence) and elevated Lp(a) (80% prevalence). Conclusion Most participants failed to meet their individual LDL-C goals according to the ESC 2016 and 2019 guidelines. In particular, high-risk patients with clinical FH or elevated Lp(a) rarely met their target for LDL-C. The identification of these patients and more intense treatment approaches are crucial for the improvement of CAD primary and secondary prevention.
引用
收藏
页数:12
相关论文
共 53 条
[1]   Assessing risk of myocardial infarction and stroke: new data from the Prospective Cardiovascular Munster (PROCAM) study [J].
Assmann, G. ;
Schulte, H. ;
Cullen, P. ;
Seedorf, U. .
EUROPEAN JOURNAL OF CLINICAL INVESTIGATION, 2007, 37 (12) :925-932
[2]   Association Between Family History and Coronary Heart Disease Death Across Long-Term Follow-Up in Men The Cooper Center Longitudinal Study [J].
Bachmann, Justin M. ;
Willis, Benjamin L. ;
Ayers, Colby R. ;
Khera, Amit ;
Berry, Jarett D. .
CIRCULATION, 2012, 125 (25) :3092-3098
[3]   A Modern Approach to Dyslipidemia [J].
Berberich, Amanda J. ;
Hegele, Robert A. .
ENDOCRINE REVIEWS, 2022, 43 (04) :611-653
[4]   LDL-cholesterol goal achievement, cardiovascular disease, and attributed risk of Lp(a) in a large cohort of predominantly genetically verified familial hypercholesterolemia [J].
Bogsrud, Martin P. ;
Graesdal, Asgeir ;
Johansen, Dan ;
Langslet, Gisle ;
Hovland, Anders ;
Arnesen, Kjell-Erik ;
Mundal, Liv J. ;
Retterstol, Kjetil ;
Wium, Cecilie ;
Holven, Kirsten B. .
JOURNAL OF CLINICAL LIPIDOLOGY, 2019, 13 (02) :279-286
[5]   Non-HDL-cholesterol and apolipoprotein B compared with LDL-cholesterol in atherosclerotic cardiovascular disease risk assessment [J].
Carr, Stuart S. ;
Hooper, Amanda J. ;
Sullivan, David R. ;
Burnett, John R. .
PATHOLOGY, 2019, 51 (02) :148-154
[6]  
Catapano Alberico L, 2017, Rev Esp Cardiol (Engl Ed), V70, P115, DOI 10.1016/j.rec.2017.01.002
[7]   Cardiovascular Risk-Estimation Systems in Primary Prevention Do They Differ? Do They Make a Difference? Can We See the Future? [J].
Cooney, Marie Therese ;
Dudina, Alexandra ;
D'Agostino, Ralph ;
Graham, Ian M. .
CIRCULATION, 2010, 122 (03) :300-310
[8]   Prevalence of familial hypercholesterolemia in patients with premature myocardial infarction [J].
Cui, Yuxia ;
Li, Sufang ;
Zhang, Feng ;
Song, Junxian ;
Lee, Chongyou ;
Wu, Manyan ;
Chen, Hong .
CLINICAL CARDIOLOGY, 2019, 42 (03) :385-390
[9]   Genome-wide association study of genetic determinants of LDL-c response to atorvastatin therapy: importance of Lp(a) [J].
Deshmukh, Harshal A. ;
Colhoun, Helen M. ;
Johnson, Toby ;
McKeigue, Paul M. ;
Betteridge, D. John ;
Durrington, Paul N. ;
Fuller, John H. ;
Livingstone, Shona ;
Charlton-Menys, Valentine ;
Neil, Andrew ;
Poulter, Neil ;
Sever, Peter ;
Shields, Denis C. ;
Stanton, Alice V. ;
Chatterjee, Aurobindo ;
Hyde, Craig ;
Calle, Roberto A. ;
DeMicco, David A. ;
Trompet, Stella ;
Postmus, Iris ;
Ford, Ian ;
Jukema, J. Wouter ;
Caulfield, Mark ;
Hitman, Graham A. .
JOURNAL OF LIPID RESEARCH, 2012, 53 (05) :1000-1011
[10]   Value of Measuring Lipoprotein(a) During Cascade Testing for Familial Hypercholesterolemia [J].
Ellis, Katrina L. ;
Perez de Isla, Leopoldo ;
Alonso, Rodrigo ;
Fuentes, Francisco ;
Watts, Gerald F. ;
Mata, Pedro .
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2019, 73 (09) :1029-1039